Nothing Special   »   [go: up one dir, main page]

EA200702349A1 - Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат - Google Patents

Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат

Info

Publication number
EA200702349A1
EA200702349A1 EA200702349A EA200702349A EA200702349A1 EA 200702349 A1 EA200702349 A1 EA 200702349A1 EA 200702349 A EA200702349 A EA 200702349A EA 200702349 A EA200702349 A EA 200702349A EA 200702349 A1 EA200702349 A1 EA 200702349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
folate
deficiency
estrogens
pharmaceutical composition
Prior art date
Application number
EA200702349A
Other languages
English (en)
Other versions
EA014664B1 (ru
Inventor
Кай Штротманн
Гейвин Уэлч Смит
Кристина Кинг
Рудольф Мозер
Клаус Питрцик
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Мерк Эпрова Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200702349(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed by Байер Шеринг Фарма Акциенгезельшафт, Мерк Эпрова Аг filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of EA200702349A1 publication Critical patent/EA200702349A1/ru
Publication of EA014664B1 publication Critical patent/EA014664B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей гестагены, преимущественно дроспиренон, эстрогены, преимущественно этинилэстрадиол и 5-метил-(6S)-тетрагидрофолат, которая может использоваться в качестве перорального контрацептива и при этом у принимающих его женщин предупреждает заболевания, вызванные недостатком фолата, в частности заболевания сердца и кровообращения и после зачатия эмбриона врожденные пороки развития, вызванные недостатком фолата, такие как, например, дефекты нервной трубки, дефект межжелудочковой перегородки, урогенитальные дефекты, а также заячья губа, волчья пасть и расщепление неба, при этом, не скрывая симптомы недостатка витамина В, и одновременно также в случае наличия гомо- или гетерозиготного полиморфизма метилентетрагидрофолат редуктазы облегчает неограниченную приемлемость организмом компонентов фолата 5-метил-(6S)-тетрагидрофолата и вместе с тем их биологическую активность для предупреждения вышеуказанных врожденных пороков развития, вызванных недостатком фолата. Более того, продолжительное защитное действие поддерживается и после прекращения приема конрацептива.
EA200702349A 2005-05-13 2006-05-15 Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат EA014664B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
PCT/EP2006/004858 WO2006120035A2 (de) 2005-05-13 2006-05-15 Pharmazeutische zusammensetzung enthaltend gestagene und/oder estrogene und 5-methyl-(6s)-tetrahydrofolat

Publications (2)

Publication Number Publication Date
EA200702349A1 true EA200702349A1 (ru) 2008-04-28
EA014664B1 EA014664B1 (ru) 2010-12-30

Family

ID=37396913

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200702349A EA014664B1 (ru) 2005-05-13 2006-05-15 Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат
EA200901393A EA028530B1 (ru) 2005-05-13 2006-05-15 Способ получения лекарственного средства, используемого в качестве контрацептива и предотвращающего заболевания и пороки развития, вызванные недостатком фолата, при этом не скрывая симтома недостатка витамина в

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200901393A EA028530B1 (ru) 2005-05-13 2006-05-15 Способ получения лекарственного средства, используемого в качестве контрацептива и предотвращающего заболевания и пороки развития, вызванные недостатком фолата, при этом не скрывая симтома недостатка витамина в

Country Status (38)

Country Link
US (2) US20080160004A1 (ru)
EP (3) EP2298307A1 (ru)
JP (2) JP2008540482A (ru)
KR (2) KR101598735B1 (ru)
CN (2) CN101954083A (ru)
AR (1) AR054123A1 (ru)
AT (2) ATE429917T1 (ru)
AU (1) AU2006245921A1 (ru)
BR (1) BRPI0611443B8 (ru)
CA (1) CA2608639C (ru)
CL (2) CL2009002187A1 (ru)
CR (1) CR9531A (ru)
CY (2) CY1109261T1 (ru)
DE (1) DE502006003617D1 (ru)
DK (2) DK1888077T3 (ru)
DO (1) DOP2006000110A (ru)
EA (2) EA014664B1 (ru)
EC (1) ECSP078001A (ru)
ES (2) ES2325600T3 (ru)
GT (1) GT200600200A (ru)
HK (1) HK1118729A1 (ru)
HR (1) HRP20090418T1 (ru)
IL (1) IL187340A (ru)
MA (1) MA29448B1 (ru)
MY (1) MY147362A (ru)
NO (1) NO345807B1 (ru)
PE (1) PE20061415A1 (ru)
PL (2) PL2116249T3 (ru)
PT (2) PT2116249E (ru)
RS (2) RS52651B (ru)
SG (1) SG169973A1 (ru)
SI (2) SI2116249T1 (ru)
SV (1) SV2008002527A (ru)
TN (1) TNSN07418A1 (ru)
TW (1) TWI380820B (ru)
UY (1) UY29527A1 (ru)
WO (1) WO2006120035A2 (ru)
ZA (1) ZA200710811B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
MX2009000256A (es) * 2006-07-06 2009-02-18 Bayer Schering Pharma Ag Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
MX2009010763A (es) * 2007-04-05 2009-10-28 Bayer Schering Pharma Ag NUEVO REGIMEN DE DROSPIRENONA/17ß-ESTRADIOL, PRODUCTO FARMACEUTICO COMBINADO Y CONJUNTO DE ELEMENTOS (KIT) PARA SU APLICACION.
AU2008341138A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
KR20130097073A (ko) 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN107812195B (zh) * 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
TR201808438T4 (tr) 2015-06-18 2018-07-23 Mithra Pharmaceuticals S A Estetrol bileşeni içeren ağızda dağılan dozaj birimi.
ME03728B (me) 2015-06-18 2021-01-20 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
JPH11513989A (ja) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
AU722050B2 (en) 1996-01-31 2000-07-20 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
EP2002839A1 (en) 1998-04-17 2008-12-17 Ortho McNeil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
EP1121139A1 (en) * 1998-10-19 2001-08-08 MERCK PATENT GmbH Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
ATE429231T1 (de) 1999-08-31 2009-05-15 Bayer Schering Pharma Ag Pharmazeutische kombination von ethinylestradiol und drospirenon als empfängnisverhütendes mittel
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
JP2004538262A (ja) * 2000-12-14 2004-12-24 タフツ ユニバーシティー 関節炎状態を治療するための化合物および方法
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
AU2002343249B2 (en) * 2002-02-21 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin B12
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
ATE555791T1 (de) 2012-05-15
DK1888077T3 (da) 2009-08-17
BRPI0611443B8 (pt) 2021-05-25
DOP2006000110A (es) 2012-06-15
KR20080028369A (ko) 2008-03-31
CL2010000989A1 (es) 2011-02-18
TW200711651A (en) 2007-04-01
ES2325600T3 (es) 2009-09-09
CA2608639C (en) 2013-04-30
EP1888077A2 (de) 2008-02-20
PL2116249T3 (pl) 2013-06-28
EA200901393A1 (ru) 2010-02-26
TWI380820B (zh) 2013-01-01
KR101598735B1 (ko) 2016-03-02
EP2116249A1 (de) 2009-11-11
DK2116249T3 (da) 2012-08-20
EP2116249B2 (de) 2023-04-05
RS52651B (en) 2013-06-28
ECSP078001A (es) 2008-01-23
ES2387525T5 (es) 2024-07-05
PT1888077E (pt) 2009-07-20
EA028530B1 (ru) 2017-11-30
PT2116249E (pt) 2012-08-07
BRPI0611443B1 (pt) 2020-07-21
CL2009002187A1 (es) 2010-10-01
US20080160004A1 (en) 2008-07-03
HRP20090418T1 (en) 2009-09-30
EA014664B1 (ru) 2010-12-30
TNSN07418A1 (en) 2009-03-17
SV2008002527A (es) 2008-03-27
JP5883810B2 (ja) 2016-03-15
CY1114403T1 (el) 2016-08-31
ES2387525T3 (es) 2012-09-25
CA2608639A1 (en) 2006-11-16
CY1109261T1 (el) 2014-07-02
SI2116249T1 (sl) 2013-02-28
PE20061415A1 (es) 2007-01-26
ZA200710811B (en) 2012-06-27
BRPI0611443A2 (pt) 2010-09-08
MY147362A (en) 2012-11-30
WO2006120035A2 (de) 2006-11-16
CR9531A (es) 2008-02-21
US10463666B2 (en) 2019-11-05
EP1888077B1 (de) 2009-04-29
DE502006003617D1 (de) 2009-06-10
ATE429917T1 (de) 2009-05-15
AR054123A1 (es) 2007-06-06
KR20140069175A (ko) 2014-06-09
PL1888077T3 (pl) 2009-12-31
WO2006120035A3 (de) 2007-02-15
NO345807B1 (no) 2021-08-16
EP2116249B1 (de) 2012-05-02
MA29448B1 (fr) 2008-05-02
RS50972B (sr) 2010-10-31
JP2008540482A (ja) 2008-11-20
JP2013166753A (ja) 2013-08-29
US20160095860A1 (en) 2016-04-07
SI1888077T1 (sl) 2009-10-31
UY29527A1 (es) 2006-12-29
CN101198332B (zh) 2012-07-18
IL187340A0 (en) 2011-08-01
NO20076408L (no) 2008-02-12
AU2006245921A1 (en) 2006-11-16
CN101198332A (zh) 2008-06-11
CN101954083A (zh) 2011-01-26
SG169973A1 (en) 2011-04-29
GT200600200A (es) 2007-03-23
HK1118729A1 (en) 2009-02-20
EP2298307A1 (de) 2011-03-23
IL187340A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
EA200702349A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат
Smith-Whitley Reproductive issues in sickle cell disease
Fisher et al. What is in our environment that effects puberty?
Rentesi et al. Long-term consequences of early maternal deprivation in serotonergic activity and HPA function in adult rat
JP5623273B2 (ja) エストリオールの低用量での使用
Spiegelstein et al. Embryonic development of folate binding protein‐1 (Folbp1) knockout mice: effects of the chemical form, dose, and timing of maternal folate supplementation
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
ECSP099030A (es) Composición farmacéutica que contiene un ácido tetrahidrofólico
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
Kalisch-Smith et al. Alcohol exposure impairs trophoblast survival and alters subtype-specific gene expression in vitro
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
Zohar et al. Sex dependent reduction by prenatal stress of the expression of 5HT1A receptors in the prefrontal cortex and CRF type 2 receptors in the raphe nucleus in rats: reversal by citalopram
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
Crandell et al. A literature review of the effects of copper intrauterine devices on blood copper levels in humans
Murray et al. Developmental toxicity study of sodium molybdate dihydrate administered in the diet to Sprague Dawley rats
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
Breseghelo et al. Nitric oxide concentration and other salivary changes after insertion of new complete dentures in edentulous subjects
Reidenberg Environmental inhibition of 11β-hydroxysteroid dehydrogenase
Bannbers et al. Lower levels of prepulse inhibition in luteal phase cycling women in comparison with postmenopausal women
JOP20100287B1 (ar) مركب دوائي يشتمل على بروجستينات واستروجينات، احدهما او كلاهما، و5 - مثيل - (6s)- رابع هايدروفولات
Xu et al. Autophagy regulates age‐related delayed jawbone regeneration and decreased osteoblast osteogenesis by degrading FABP3
Battaglia et al. L-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study
El-Gharib Hyperhomocysteinemia and polycystic ovary syndrome
Allam et al. The effect of folic acid in women with recurrent pregnancy loss, polycystic ovary syndrome and hyperhomocysterinemia
MD3222G2 (ru) Метод диагностики рака эндометрия

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent
TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
ND4A Extension of term of a eurasian patent